Category Archives: Disease

UK’s Momentum Bio could help millions of hospital patients with first diagnostic test for blood infections that says whether or not to use antibiotics.

The News: Momentum Biosciences Ltd. (Cardiff UK) aims to pare back the unnecessary use of antimicrobial drugs in hospitals. To do this, it is developing molecular diagnostics that, within hours,… Read more »

Maat Pharma’s microbiome therapy shows early promise in cancer patients treatment. Are common gut bugs leading the charge to investment riches?

The News: A clinical trial run by MaaT Pharma SA (Lyon FRA) has shown that restoring the microbiome of patients undergoing chemotherapy has potential to improve the outcome of patients… Read more »

This Dutch biotech startup is quietly developing a novel immune-cell approach for cancer. Can it muscle in on established rivals?

The News: Lava Therapeutics BV (Hertogenbosch NLD) is quietly developing a cancer immunotherapy that arms a rare type of immune cell called gamma delta T cells, Labiotech.eu reports. The company’s… Read more »

Moderna launches biggest biotech IPO ever, but shares immediately crash. Is this a buying opportunity?

The News: Moderna Therapeutics Inc. (Cambridge MA) watched its share price nosedive within hours of pulling off the biggest initial public offering in biotech history, a sign the company and its underwriters… Read more »

Tissue engineering and regenerative medicine starting to elbow its way into media coverage; watch out you cancer “miracle cures.”

The News: A group of researchers in Spain has developed a silk biomaterial that can increase the survival of transplanted stem cells into the brain, improving recovery after a stroke… Read more »

England’s biotech startup Sitryx out of the blocks with new I/O program. Stakes are high as Europe’s science contending with US for top global developers.

The News: Sitryx Therapeutics Ltd. (London) has launched with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising new area of research…. Read more »

FDA clears psilocybin for testing as breakthrough therapy

UPDATE: FDA permits psilocybin to be tested for refractory depression; grants Breakthrough Therapy designation for magic mushrooms psychedelic compound. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy… Read more »

Europe bursts onto the biotech scene as Grifols’ Phase 2b/3 plasma replacement therapy works in Alzheimer’s patients. Buy, sell or hold?

The News: A blood plasma replacement therapy from Spanish company Grifols SA (Barcelona) reduced cognitive decline by 61% in patients with moderate Alzheimer’s disease compared with placebo, Labiotech.eu reports. The… Read more »

Stodgy Johns Hopkins wants FDA to clear psilocybin mushrooms for depression. Here’s what you need to know (or recall) about the differences between magic shrooms and, say, LSD.

The News: Researchers from Johns Hopkins University (Baltimore) have recommended that psilocybin, the active compound in hallucinogenic mushrooms, be reclassified for medical use, potentially paving the way for the psychedelic… Read more »

Atrial fibrillation increases risk of dementia by 40%, Swedish study shows. Bring on those blood thinners, say researchers.

The News: New evidence suggests that atrial fibrillation, in which the heart has an irregular beat, is linked to an increased risk of dementia. An irregular heartbeat speeds up the… Read more »